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Etiologic studies of acute febrile disease were con-
ducted in sites across South America, including Cusco and 
Iquitos, Peru. Patients’ clinical signs and symptoms were 
recorded, and acute- and convalescent-phase serum sam-
ples were obtained for serologic examination and virus iso-
lation in Vero E6 and C6/36 cells. Virus isolated in Vero E6 
cells was identiﬁ  ed as encephalomyocarditis virus (EMCV) 
by electron microscopy and by subsequent molecular diag-
nostic testing of samples from 2 febrile patients with nau-
sea, headache, and dyspnea. The virus was recovered from 
acute-phase serum samples from both case-patients and 
identiﬁ   ed with cardiovirus-speciﬁ   c reverse transcription–
PCR and sequencing. Serum samples from case-patient 1 
showed cardiovirus antibody by immunoglobulin M ELISA 
(acute phase <8, convalescent phase >1,024) and by neu-
tralization assay (acute phase <10, convalescent phase 
>1,280). Serum samples from case-patient 2 did not contain 
antibodies detectable by either assay. Detection of virus in 
serum strongly supports a role for EMCV in human infection 
and febrile illness.   
E
ncephalomyocarditis virus (EMCV; family Picorna-
viridae, genus Cardiovirus) is a group of closely re-
lated virus strains belonging to 1 serotype with a wide host 
range (1). Infection with EMCV is associated with sporadic 
cases and outbreaks of myocarditis and encephalitis in do-
mestic pigs, in numerous species of nonhuman primates, 
and in other mammalian species (2–8). The disease is of-
ten fatal—frequently, sudden death is the ﬁ  rst indication 
of infection—and most outbreaks have been associated 
with captive animals, such as those found in piggeries, 
primate research centers, and zoos. Virus isolation and se-
rologic studies indicate EMCV is distributed worldwide, 
but clinical disease in humans or domestic animals is rela-
tively infrequent. Although disease transmission is poorly 
understood, rodents appear to be the natural reservoirs (1). 
Rodent infestation has been implicated in the genesis of 
several epizootics; disease transmission apparently results 
from close contact between rodents or their excreta and in-
dividuals of susceptible mammalian species (1,2,4,5,8,9). 
In several instances, rodent control measures have inter-
rupted disease transmission and halted institutional epi-
zootics (4).
Human EMCV infection and disease have been doc-
umented by virus isolation from several specimen types, 
including serum, stool samples, cerebral spinal ﬂ  uid, and 
throat washings (10–12). However, because this disease is 
so infrequent in humans, positive association with EMCV 
is difﬁ  cult to establish. In addition, results of several early 
studies were questionable because EMCV was isolated by 
using laboratory mice; researchers could not unequivocally 
establish that the virus did not originate from the mice used 
for isolation and passage rather than from human clinical 
specimens (12). Recently, a novel cardiovirus, Saffold vi-
rus (SAFV; genus Theilovirus), was reported in associa-
tion with fever of unknown origin in a child 8 months of 
age (13) and in children with symptoms of respiratory or 
gastrointestinal illness (14–16). This ﬁ  nding suggests that 
additional cardioviruses may be pathogenic for humans. 
Serologic studies also indicate that humans have been in-
fected by EMCV or immunologically related viruses (17–
22). Antibody prevalence varied somewhat from study to 
study, but seropositivity rates tended to increase in persons 
of advancing age, consistent with a continuous risk for in-
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fection throughout life. In early 2004, we identiﬁ  ed EMCV 
infection in serum samples from 2 febrile patients in Peru.  
Materials and Methods
Surveillance System 
In collaboration with the Peruvian Ministry of Health, 
the Naval Medical Research Center Detachment, Lima, 
Peru, has established a febrile illness surveillance program 
designed to identify the causes of febrile diseases in the 
country. The program carries out passive surveillance in 
Ministry of Health posts, where febrile patients are identi-
ﬁ  ed, signs and symptoms are recorded, and acute- and con-
valescent-phase blood samples are collected for diagnostic 
studies. Tests routinely performed in support of the surveil-
lance program include immunoglobulin (Ig) M ELISA for 
ﬂ  aviviruses, alphaviruses, bunyaviruses, arenaviruses, and 
rickettsia, as well as virus isolation, reverse transcription–
PCR (RT-PCR), and sequencing. The study protocol was 
approved by the Naval Medical Research Center Institu-
tional Review Board (Protocol NMRCD.2000.0006, De-
partment of Defense 31535), in compliance with all federal 
regulations governing the protection of human patients; 
the protocol also was reviewed by the Peruvian Ministry 
of Health.
Case Deﬁ  nitions 
Clinical diagnoses were considered conﬁ  rmed if labo-
ratory testing resulted in isolation of virus from the speci-
men, virus detection by RT-PCR, or a 4-fold or greater in-
crease in IgM antibody titers. Diagnoses were considered 
presumptive if the IgM titer was elevated in the acute-phase 
sample only or a 4-fold or greater increase was discerned 
upon comparison of acute- and convalescent-phase titers. 
In the absence of laboratory evidence of a speciﬁ  c patho-
gen, cases were classiﬁ  ed as negative. 
Virus Isolation
Viruses were isolated by using a modiﬁ  cation of a pub-
lished protocol (23). Acute-phase serum samples, obtained 
no more than 5 days after disease onset, were transported 
on dry ice to the Naval Medical Research Center Detached 
laboratory in Lima and stored at –80°C. Serum samples 
were thawed and diluted 1:5 in minimum essential medium 
containing 2% heat-inactivated fetal bovine serum and an-
timicrobial agents. African green monkey (Vero) (37°C) 
and/or mosquito C6/36 (28°C) cell cultures were each in-
jected with 200 μL of the diluted serum into 25-cm2 ﬂ  asks. 
Upon observation of viral cytopathic effect, or 10 days 
postinoculation (dpi) if no cytopathic effect was observed, 
cells were removed from the ﬂ  asks and placed on 12-well 
glass spot-slides for examination by immunoﬂ  uorescence 
assay using group- and virus-speciﬁ  c polyclonal and mono-
clonal antibodies. The antibodies used were reactive with 
dengue viruses 1–4, yellow fever virus, St. Louis encepha-
litis virus, Rocio virus, Ilheus virus, West Nile virus, Ven-
ezuelan equine encephalitis virus, eastern equine encepha-
litis virus, Mayaro virus, Trocara virus, Oropouche virus, 
Caraparu virus, Murtucu virus, Guaroa virus, hantavirus, 
Machupo virus, and Tacaribe virus; after the cardiovirus 
isolation, EMCV antibody also was used.
Upon receipt of the viruses at the Centers for Disease 
Control and Prevention (CDC; Atlanta, Georgia, USA), a 
master seed stock was prepared from each virus and work-
ing stocks were made by passage in Vero E6 cells. Cyto-
pathic effect developed rapidly, and the cultures were har-
vested at 3–4 dpi; some infected cells were ﬁ  xed in 2.5% 
glutaraldehyde for electron microscopy examination. For 
virus reisolation at CDC, acute-phase serum samples were 
injected into Vero E6 cells. Virus isolates were obtained in 
Vero E6 cells from acute-phase serum of both case-patients. 
The isolates, IQD6726 (Iquitos) and FSC575 (Cusco), were 
passaged in Vero E6 cells to obtain stocks for further analy-
sis. Litters of suckling mice were inoculated intracerebrally 
with both strains of virus. Brain, spleen, and liver tissues 
were harvested and ﬁ  xed in 2.5% glutaraldehyde for elec-
tron microscopic examination. 
RNA Extraction, RT-PCR, and Sequencing 
RNA was extracted from the virus isolates by using the 
QIAamp Viral RNA Mini Kit (QIAGEN, Valencia, CA, 
USA). cDNA reactions consisted of 2 μL of extracted vi-
ral RNA, 50 ng of random hexamers (Applied Biosystems, 
Foster City, CA, USA), 4 μL of 5× ﬁ  rst strand buffer (In-
vitrogen, Carlsbad, CA, USA), 200 μmol/L of each dNTP 
(GE Healthcare, Piscataway, NJ, USA), 40 U of RNasin 
ribonuclease inhibitor (Promega, Madison, WI, USA), and 
200 U of SuperScript II reverse transcriptase (Invitrogen) in 
a total volume of 20 μL. The cDNA reactions were incu-
bated for 10 min at 25°C, followed by 45 min at 42°C and 
4 min at 95°C. For the PCR assays, 3 genome regions were 
targeted, the 5′-NTR, VP1, and 3D regions (Table). Two sets 
of PCR primers targeting the viral protein 1 (VP1) gene were 
used, yielding overlapping PCR fragments. PCR reactions 
consisted of 2 μL of cDNA, 200 μmol/L of each dNTP (GE 
Healthcare), 5 μL of 10× buffer with MgCl2 (Roche Molecu-
lar Biochemicals, Indianapolis, IN, USA), 2.5 U of Fast Start 
Taq DNA Polymerase (Roche), and forward and reverse 
primers (10 pmol of each of AN312 and AN315; 40 pmol 
each of AN283, AN285, AN393, and AN286; 20 pmol each 
of P1 and P2; and 60 pmol each of 1C340F and 2B188R), in 
a total volume of 50 μL. Cycling parameters were 42ºC for 
50 min, 50°C for 10 min, and 95ºC for 5 min, followed by 
45 cycles of 95ºC for 30 sec, 45ºC for 40 sec, and 60ºC for 1 
min. All PCR products were analyzed by electrophoresis in 
2% agarose gels stained with ethidium bromide.
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Amplicons were puriﬁ  ed from an agarose gel (QIA-
GEN gel extraction kit) before sequencing. Both strands 
were sequenced by using the PCR primers, a Prism Big-
Dye Terminator version 1.1 or 3.1 Ready Reaction Cycle 
Sequencing kit (Applied Biosystems), and a model 3100 
or 3130 Genetic Analyzer (Applied Biosystems). The se-
quences determined in this study were deposited in the 
GenBank sequence database, accession nos. EU979543–
EU979548. 
Sequences were identiﬁ   ed in GenBank by using 
BLAST to compare sequences (www.ncbi.nlm.nih.gov/
blast). For phylogenetic reconstruction, sequences were 
aligned with those of other cardioviruses by using PileUp 
(Wisconsin Sequence Package, version 11.1; Accelrys, 
San Diego, CA, USA), and trees were generated with the 
neighbor-joining method implemented in ClustalX version 
1.83 (25). Genetic distances were estimated by the Kimura 
2-parameter method. To assess the conﬁ  dence of branching 
patterns of the neighbor-joining tree, 1,000 bootstrap repli-
cates were performed. 
Serologic Testing
Serum specimens were tested for neutralizing anti-
body against EMCV by a modiﬁ  ed microneutralization 
assay (26). Approximately 80–100 median 50% cell cul-
ture infectious dose (CCID50) of isolate FSC575 and serial 
dilutions of serum (starting at 1:10 and ending at 1:1,280) 
were incubated together at 37°C for 2.5 h before Vero E6 
cells were added to the wells. After incubation for 5 days 
at 37°C, each plate was stained with 0.05% crystal violet in 
25% ethyl alcohol and, after drying, the optical density in 
each well was measured at 570 nm. Each specimen was run 
in triplicate; the ﬁ  nal titer was estimated by use of the Spear-
man-Karber method (27). Positive-control anti-EMCV 
serum was generously provided by Ann Palmenberg.
Pathogen-speciﬁ  c IgM titers were determined by us-
ing an adapted IgM-capture ELISA (28). Brieﬂ  y, 96-well 
plates were coated with antihuman IgM antibody to capture 
patient IgM molecules. Virus-speciﬁ  c IgM was detected by 
adding viral antigen, followed by virus-speciﬁ  c mouse hy-
perimmune ascitic ﬂ  uid and horseradish peroxidase-labeled 
antimouse IgG. After the addition of colorimetric substrate, 
absorbance was read at 490 nm. All acute- and convales-
cent-phase samples were initially screened at 1:100. Sam-
ples exceeding the reference cutoff value, calculated as the 
median of 7 antibody-negative samples plus 3 standard de-
viations, were considered IgM positive. Positive samples 
were subsequently retested by using 4-fold serial dilutions 
to determine end-point titers. Viruses included in the ELI-
SAs included dengue viruses 1–4, yellow fever virus, St. 
Louis encephalitis virus, Rocio virus, Ilheus virus, West 
Nile virus, Venezuelan equine encephalitis virus, eastern 
equine encephalitis virus, Mayaro virus, Trocara virus, 
Oropouche virus, Caraparu virus, Murtucu virus, Guaroa 
virus, hantavirus, Machupo virus, and Tacaribe virus; after 
the cardiovirus isolation, EMCV was also used.
Results
Clinical Description of Cases
The ﬁ  rst patient was identiﬁ  ed in the Amazonian city 
of Iquitos, Loreto Department, Peru. Iquitos (3°44.69′S, 
73°15.25′W) is situated at an elevation of 120 m and has 
a population of ≈350,000. The city is surrounded by the 
Nanay, Itaya, and Amazon rivers and is accessible only by 
air or river. The climate is tropical, mean temperature is 
25°C, and annual rainfall is 2.7 m. Rodents are common in 
urban and rural areas; swine and primates are abundant in 
rural zones. 
Case-patient 1 was a 59-year-old housewife from Iq-
uitos. She sought treatment at Hospital Apoyo Iquitos af-
ter 3 days of fever, pallor, poor appetite, malaise, nausea, 
and headache. She recovered completely from fever after 
6 days of treatment as an outpatient. Acute-phase (3 days 
postonset), convalescent-phase (15 days postonset), and 
late convalescent–phase (8 months later) blood samples 
were obtained. She had no identiﬁ  able focus of infection, 
negative thick and thin smears for malaria, and a negative 
tourniquet test. She reported no yellow fever or hepatitis 
B vaccination and no travel outside of Iquitos within 2 
weeks before onset. The patient was interviewed 8 months 
after seeking treatment when virus isolation results were 
completed. She reported only limited contact with rats and 
cats in her house and a neighbor’s house where she played 
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Table. Oligonucleotide primers used for cardiovirus PCR amplification and sequencing* 
Primer  Sequence (5ƍ ĺ 3ƍ)  Region  Coordinates  Reference 
AN312  GARTVWCGYRAAGRAAGCAGT  5ƍ-NTR  455–475   This study 
AN315  GGYRCTGGGGTTGYRCCGC  5ƍ-NTR  618–600  This study 
AN283  GCAGACGGWTGGGTNACNGTNTGG  VP3  2559–2582  This study 
AN285  AGAGTAACCTCTACRTCRCAYTTRTA  VP1  3097–3072  This study 
AN393  TTTCCACTCAAGTCTAARCARGAYT  VP1  3015–3049  This study 
AN286  AAGAAGACAGTCGGACGNGGRCARAANAC  VP1  3472–3444  This study 
P1  CCCTACCTCACGGAATGGGGCAAAG  3D  7655–7631  (24) 
P2  GGTGAGAGCAAGCCTCGCAAAGACAG  3D  7370–7395  (24) 
*NTR, nontranslated region; VP1, viral protein 1. Encephalomyocarditis Virus Infection, Peru
bingo frequently. After 7 days and nights of trapping in both 
houses and in a sewer adjacent to the neighbor’s house, no 
rodents were collected.
The second case-patient was identiﬁ  ed in the Cusco 
Regional Hospital but had traveled from Quebrada, a small 
rural village on the Yanatile River, about 8 hours travel time 
from the city of Cusco. Quebrada (approximately 13°55′S, 
71°40′W) is located in Yanatile district, Calca Province, 
in the Department of Cusco. The weather in Quebrada is 
warmer than that in Cusco (temperate climate) at an altitude 
of 2,926 m. Malaria and leishmaniasis are endemic to the 
area. The city is accessible by air and land from Cusco. 
Case-patient 2 was a 39-year-old male farmer from 
Cusco-Acomayo/Quebrada Calca. He sought treatment at 
the local hospital after 7 days of fever. Additional symp-
toms were headache, malaise, retro-ocular pain, sweats, 
weight loss, arthralgia, photophobia, poor appetite, myal-
gia, chills, pallor, nausea, vomiting, and abdominal pain. 
He was hospitalized with a diagnosis of febrile syndrome 
and urinary tract infection (UTI). Urinalysis showed 20–
25 leukocytes per high-power ﬁ  eld. The patient had ele-
vated values for alkaline phosphatase (680 U/L; reference 
range 68–240 U/L), total bilirubin (1.68 mg/dL; reference 
value <1.0 mg/dL), and direct bilirubin (1.06 mg/dL; ref-
erence value <0.2 mg/dL). Thick and thin smears for ma-
laria and Bartonella spp. were negative, as were urine cul-
ture and a tourniquet test for dengue hemorrhagic fever. 
The patient was treated with oral ciproﬂ  oxacin (750 mg 
2×/d for 7 days), oral paracetamol (acetaminophen; 500 
mg as needed for fever >38.5ºC), and intravenous ﬂ  uids. 
He recovered completely after 7 days as an inpatient. At 
the time of his convalescent-phase sample (15 days pos-
tonset), his physical examination was within normal lim-
its. He reported tuberculosis in a family member contact 
(treated for 5 months), yellow fever vaccination in 1994, 
and no vaccination against hepatitis B. No case investiga-
tion was carried out for this patient to determine risk fac-
tors for disease. However, the typically rural populations 
near Cusco have contact with a variety of animal species 
such as mules, dogs, cats, swine, rodents, rabbits, llamas, 
alpacas, and vicuñas.
Virus Isolation and Identiﬁ  cation 
Virus isolates were obtained from acute-phase serum 
specimens of both patients by inoculation of Vero E6 cell 
cultures. Electron microscopic studies of infected Vero E6 
cells and mouse tissues demonstrated cytoplasmic accumu-
lations of particles consistent with the features of picorna-
viruses. Virions averaged 24 nm in diameter and were oc-
casionally found in paracrystalline arrays (Figure 1, panel 
A). The infected cells were notable for areas of vesiculation 
and membrane proliferation (Figure 1, panel C), consistent 
with the replication complexes, which have been described 
for picornavirus-infected cells (29). Newborn mice inocu-
lated intracerebrally all died at 3 dpi. Rapid death in neonatal 
mice, coupled with ultrastructural evidence of picornavirus 
infection, was consistent with the presence of a cardiovirus. 
To conﬁ  rm the diagnosis, we used cardiovirus-speciﬁ  c 
RT-PCR assays targeting the 5′-nontranslated region and 
the VP1 and 3D coding regions (Table). Each of the cardio-
virus-speciﬁ  c primer sets ampliﬁ  ed a speciﬁ  c DNA product 
of the expected size; in each instance, the identity of the 
amplicon was conﬁ  rmed by sequencing. In a phylogenetic 
reconstruction done on the basis of sequences from the VP1 
capsid region, the Peru viruses clustered with sequences of 
EMCV strains derived from pigs from Belgium, Cyprus, 
and Italy; the EMCV reference strains and ﬁ  eld strains from 
pigs and orangutans formed separate subgroups within the 
EMCV species group (Figure 2, panel A). The VP1 nucle-
otide sequences of the Peru strains were 91%–100% identi-
cal to those of other strains within their phylogenetic sub-
group. VP1 nucleotide identities of the Peru cardioviruses 
to the other EMCV subgroups ranged from 71% to 80% 
and from 47% to 51% to the rodent and human viruses in 
the Theilovirus genus, respectively. The Peru strains were 
also most closely related to the European pig strains in the 
5′-NTR and 3D regions (Figure 2, panels B, C). Within the 
larger EMCV 5′-NTR group, containing the Peru cardiovi-
ruses, pairwise nucleotide identities ranged from 95.8% to 
100.0% (Figure 2, panel B). Relatedness of the Peru cardio-
viruses’ 5′-NTR to the EMCV and Theiler’s viruses outside 
of this group ranged from 30.3% to 58.4%. Within the large 
3D clade containing the Peru cardioviruses and European 
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Figure 1. Ultrastructural morphologic features of cardiovirus-infected Vero E6 cells. A) Collections of picornavirus particles, some arranged 
in a paracrystalline array (arrow). Scale bar = 100 nm. B) Higher magniﬁ  cation of area pointed to by arrowhead in panel C showing 
condensed material (arrow) at periphery of a viral cluster. Scale bar = 100 nm. C) Cardiovirus-infected cell, showing membrane proliferation 
and vesiculation (arrows). Scale bar = 1 μm. THE AMAZON REGION  RESEARCH
pig strains (Figure 2, panel C), the nucleotide identities 
ranged from 95.2% to 100.0%. 3D nucleotide identities of 
the Peru cardioviruses to the EMCVs outside the Peru clade 
ranged from 80.0% to 87.6%. Relatedness of the Peru car-
dioviruses’ 3D region to the Theiler’s viruses ranged from 
56.7% to 61.4%.
Serologic Conﬁ  rmation of Infection
Serum from case-patient 1 was seropositive for car-
diovirus by IgM monoclonal antibody-capture ELISA; titer 
was high. Seroconversion was documented by an increase 
in titer from <8 in the acute-phase sample (day 3) to >1,024 
in the convalescent-phase sample (day 15). The neutraliza-
tion assay yielded similar results; acute-phase titer was <10 
and a convalescent-phase titer was >1,280. Serum samples 
from case-patient 2, collected on days 7 and 15, were nega-
tive in both assays (titers <8 and <10, respectively), despite 
the presence of virus in the day 7 serum sample.
Discussion
Our ongoing febrile surveillance studies identiﬁ  ed 
and documented 2 cases of human EMCV disease, each 
of which was diagnosed by virus isolation from acute-
phase serum. One patient had an undifferentiated fever 
with complete recovery after 6 days of fever. The second 
patient’s disease was complicated by concomitant UTI, 
which presumably prolonged the course of disease (11 
days of fever). Even though EMCV was isolated from this 
patient, we cannot be certain whether speciﬁ  c symptoms 
resulted from the viral infection or from the concurrent 
UTI. At the time of hospitalization, the urine culture was 
negative, but the patient had received a course of antimi-
crobial drugs before his hospitalization. However, the uri-
nary tract symptoms also could be consistent with EMCV 
infection because orchitis has been observed in male 
laboratory male mice and hamsters (30,31). Hyperbili-
rubinemia, associated with EMCV infection in humans, 
is consistent with the observation of liver compromise 
that has been well documented in laboratory studies of 
EMCV-infected mice, swine, and primates (5,32). The 2 
case-patients probably had contact with infected animals. 
The proposed routes of transmission to humans are con-
tamination of wounds and contact with domestic animals, 
such as cats, that frequently contact EMCV-infected ro-
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Figure 2. Phylogenetic relationships among viruses detected in Peru and other encephalomyocarditis viruses (EMCVs), and their 
relationship to the Theiler and Theiler-like cardioviruses. A) Viral protein 1 (VP1); 737 nucleotides (90% of the VP1 gene). The missing 
portion of the VP1 gene is at the 3’ end. B) 5′ nontranslated region; 145 nucleotides consisting of a highly conserved portion of the internal 
ribosome entry site, sequence coordinates 558 to 699 relative to EMCV GenBank accession no. AX786477. C) 3D; 210 nucleotides (15% 
of the 3D gene). The use of this portion of the 3D gene for phylogenetic analysis has been described elsewhere (25). Phylogenies were 
reconstructed with the neighbor-joining method implemented in ClustalX version 1.83 (27). Genetic distances were estimated by the 
Kimura 2-parameter method. To assess the conﬁ  dence of branching patterns, 1,000 bootstrap replicates were performed. Cardioviruses 
are identiﬁ  ed by GenBank accession number and strain name; when available, complete virus information is given, using the following 
convention: GenBank accession number, country of origin/strain name/year of isolation-host species. Country abbreviations: BEL, 
Belgium; BRA, Brazil; CAN, Canada; CYP, Cyprus; FRA, France; GER, Germany; GRE, Greece; ITA, Italy; JPN, Japan; RUS, Russia; 
SIN, Singapore; USA, United States.  Scale bars indicate number of nucleotide substitutions per site.Encephalomyocarditis Virus Infection, Peru
dents. The virus identiﬁ  ed was distinct from EMCV refer-
ence strains but closely related to EMCV strains from pigs 
in Europe in all 3 genomic regions analyzed. 
Few cases of human EMCV disease have been docu-
mented; however, in the older literature, virus isolation was 
reported from cerebrospinal ﬂ  uid, blood, feces, and throat 
washings of patients (particularly children) with aseptic 
meningitis, poliomyelitis-like paralysis, encephalomyeli-
tis, Guilláin-Barré syndrome, and fever of unknown origin 
(10–12). Human disease characterized by chills, fever, se-
vere headache, stiff neck, pleocytosis, delirium, delusions, 
vomiting, photophobia, and fever also has been reported 
(10). A novel cardiovirus, SAFV, isolated from the stool 
of an infant with fever of unknown origin, recently was re-
ported (15). SAFV and SAFV-like viruses also have been 
detected in nasopharyngeal aspirates from children with 
respiratory illness (16) or gastroenteritis (17,18). In all of 
these cases, however, virus was isolated only from speci-
mens obtained from nonsterile sites, making the patients’ 
symptoms impossible to associate unequivocally with the 
cardiovirus infection. In other human picornavirus infec-
tions, virus can sometimes be isolated from whole blood, 
serum, or plasma, but viremia is usually of short duration 
and relatively low titer (33). For enterovirus infections, for 
example, blood is not considered a reliable source of virus, 
except in very young children (34). In infants, prolonged 
enterovirus viremia may lead to multiple organ involve-
ment and more serious disease. In the 2 EMCV-infected 
patients described here, virus was isolated from serum col-
lected 3 and 7 days after onset of symptoms, respectively, 
suggesting that viremia level was high and of long dura-
tion. Together, virus isolation from serum and, for 1 case-
patient, documentation of >4-fold rise in antibody titer, 
provide conclusive evidence for causality.
Because few clinical or public health laboratories are 
capable of identifying cardiovirus infection, the effect on 
human health is unknown. The original detection and iden-
tiﬁ  cation of SAFV used a combination of traditional virus 
isolation in cell culture and creation and characterization of 
a cDNA library by DNase sequence–independent single-
primer ampliﬁ  cation (15,16). A panviral DNA microarray 
also has been used to detect SAFV and SAFV-like human 
cardioviruses (18). Such laborious methods are not practi-
cal for routine diagnostic testing. Direct detection of human 
cardioviruses by RT-PCR, as described here, or by SAFV-
speciﬁ  c RT-PCR (17), can be adapted for use in the clinical 
laboratory, and sequencing of PCR products can be used 
for conﬁ  rmation and more detailed molecular epidemiolog-
ic analysis. On the basis of an analysis of SAFV sequences, 
the PCR assays described here should efﬁ  ciently amplify 
and detect SAFV and all other known cardioviruses (data 
not shown), providing a valuable tool to detect cardiovi-
ruses in human specimens. However, before routine testing 
of human specimens can be justiﬁ  ed, studies are needed 
to assess the prevalence of cardiovirus infection in human 
populations, to associate speciﬁ  c disease syndromes with 
cardiovirus infection, and to identify reservoir species in-
volved in zoonotic transmission. These studies will help 
estimate the impact of disease caused by cardiovirus infec-
tion and identify prevention and intervention strategies.  
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